SCHEMBL3634669

SCHEMBL3634669

CCOc1cc(CN2CCC(Nc3ncc(-c4ccc(OC)cc4)o3)CC2)cc(OCC)c1-c1ccc(F)cc1

nearest known ligand 0.54

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SSTR5 P35346 20/20 0.54
KCNH2 Q12809 5/20 0.54
SSTR3 P32745 1/20 0.53
HRH1 P35367 2/20 0.47
HTR2B P41595 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3639428 0.95 SSTR5 (0.58) SSTR5KCNH2SSTR3HRH1
SCHEMBL3633654 0.92 SSTR5 (0.56) SSTR5KCNH2SSTR3HRH1
SCHEMBL3635109 0.91 SSTR5 (0.60) SSTR5KCNH2HRH1HTR2B
SCHEMBL3634851 0.89 SSTR5 (0.63) SSTR5KCNH2SSTR3HRH1
SCHEMBL3631534 0.88 SSTR5 (0.55) SSTR5KCNH2HRH1HTR2B
SCHEMBL3636107 0.87 SSTR5 (0.55) SSTR5KCNH2SSTR3HRH1HTR2B
SCHEMBL3638279 0.85 SSTR5 (0.61) SSTR5KCNH2HRH1HTR2B
SCHEMBL3634990 0.85 SSTR5 (0.59) SSTR5KCNH2HRH1HTR2B
SCHEMBL3640189 0.84 SSTR5 (0.62) SSTR5KCNH2HRH1HTR2B
SCHEMBL3635814 0.82 SSTR5 (0.68) SSTR5KCNH2HRH1HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155718-A2 ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY F. Hoffmann-Roche AG (CH) 2010-02-24 EP claimed
WO-2008148710-A2 ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINS RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2008-12-11 WO claimed
US-20080306116-A1 ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-12-11 US claimed
EP-2155718-A2 ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY F. Hoffmann-Roche AG (CH) 2010-02-24 EP disclosed
WO-2008148710-A2 ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINS RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2008-12-11 WO disclosed
US-20080306116-A1 ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306116-A1 ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES SSTR5, NPY5R, SSTR3 SSTR5 1/4885KCNH2 2416/4885SSTR3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.